Atypical antipsychotics (Second generation) updated on 06-10-2025

Postpartum hemorrhage

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18385
R77534		 Kananen - Quetiapine, 2023 Post partum bleeding (blood loss of more than 500 mL in vaginal deliveries) during pregnancy (anytime or not specified) retrospective cohort unexposed (general population or NOS) Adjustment: Yes 1.65 [1.13;2.42] 42/152   6,888/35,133 6,930 152
ref
S2378
R2911		 Frayne (Control exposed to antidepressants), 2018 Postpartum hemorrhage during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick excluded Adjustment: No 0.70 [0.26;1.87] C
excluded (control group) 		10/75   9/50 19 75
ref
S2285
R2650		 Frayne (Control unexposed, sick), 2018 Postpartum hemorrhage during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No 0.66 [0.26;1.67] C 10/75   11/58 21 75
ref
S2294
R8213		 Vigod, 2015 Peripartum haemorrhage during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed, sick Adjustment: Yes Matched 0.98 [0.64;1.49] 54/1,021   54/1,021 108 1,021
ref
Total 3 studies 1.14 [0.70;1.84] 7,059 1,248
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Kananen - Quetiapine, 2023Kananen - Quetiapine, 2023 1.65[1.13; 2.42]6,93015242%ROB confusion: seriousROB selection: unclearROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Frayne (Control unexposed, sick), 2018Frayne, 2018 1 0.66[0.26; 1.67]217518%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Vigod, 2015Vigod, 2015 0.98[0.64; 1.49]1081,02140%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 61% 1.14[0.70; 1.84]7,0591,2480.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Control unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.14[0.70; 1.84]7,0591,24861%NAKananen - Quetiapine, 2023 Frayne (Control unexposed, sick), 2018 Vigod, 2015 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.65[1.13; 2.41]6,930152 -NAKananen - Quetiapine, 2023 1 unexposed, sickunexposed, sick 0.92[0.62; 1.35]1291,0960%NAFrayne (Control unexposed, sick), 2018 Vigod, 2015 2 Tags Adjustment   - No  - No 0.66[0.26; 1.67]2175 -NAFrayne (Control unexposed, sick), 2018 1   - Yes  - Yes 1.28[0.77; 2.14]7,0381,17369%NAKananen - Quetiapine, 2023 Vigod, 2015 2 MatchedMatched 0.98[0.64; 1.50]1081,021 -NAVigod, 2015 1 All studiesAll studies 1.14[0.70; 1.84]7,0591,24861%NAKananen - Quetiapine, 2023 Frayne (Control unexposed, sick), 2018 Vigod, 2015 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 2378

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.65[1.13; 2.41]6,930152 -NAKananen - Quetiapine, 2023 1 unexposed, sick controlsunexposed, sick controls 0.92[0.62; 1.35]1291,0960%NAFrayne (Control unexposed, sick), 2018 Vigod, 2015 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.70[0.26; 1.87]1975 -NAFrayne (Control exposed to antidepressants), 2018 10.510.01.0